Wegovy, the brand name for semaglutide, is available as a weight-loss drug only: for severely obese people living with other health conditions under the supervision of specialist weight-loss programmes, access to which is, like many NHS services, constrained

In a new study, obese kids who used GLP-1 weight-loss drugs had a 33% decline in their risk for thoughts of suicide and suicide attempts compared to adolescents who didn't.

As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide and suicidal thoughts. But a new study involving more than 54,